Amgen hands back heart failure programme rights to Cytokinetics

24th November 2020 Uncategorised 0

Omecamtiv mecarbil and AMG 594 rights transitioned back to biotech

More: Amgen hands back heart failure programme rights to Cytokinetics
Source: News